215 related articles for article (PubMed ID: 17497736)
21. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
22. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
23. Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity.
Standley SM; Mende I; Goh SL; Kwon YJ; Beaudette TT; Engleman EG; Fréchet JM
Bioconjug Chem; 2007; 18(1):77-83. PubMed ID: 17226959
[TBL] [Abstract][Full Text] [Related]
24. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.
Shima F; Uto T; Akagi T; Akashi M
Bioconjug Chem; 2013 Jun; 24(6):926-33. PubMed ID: 23631730
[TBL] [Abstract][Full Text] [Related]
25. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency.
Kazzaz J; Singh M; Ugozzoli M; Chesko J; Soenawan E; O'Hagan DT
J Control Release; 2006 Feb; 110(3):566-73. PubMed ID: 16360956
[TBL] [Abstract][Full Text] [Related]
26. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice.
Mueller M; Reichardt W; Koerner J; Groettrup M
J Control Release; 2012 Aug; 162(1):159-66. PubMed ID: 22709589
[TBL] [Abstract][Full Text] [Related]
27. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination.
Bal SM; Hortensius S; Ding Z; Jiskoot W; Bouwstra JA
Vaccine; 2011 Jan; 29(5):1045-52. PubMed ID: 21129393
[TBL] [Abstract][Full Text] [Related]
28. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.
Makkouk A; Joshi VB; Wongrakpanich A; Lemke CD; Gross BP; Salem AK; Weiner GJ
AAPS J; 2015 Jan; 17(1):184-93. PubMed ID: 25331103
[TBL] [Abstract][Full Text] [Related]
29. Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity.
Rietscher R; Schröder M; Janke J; Czaplewska J; Gottschaldt M; Scherließ R; Hanefeld A; Schubert US; Schneider M; Knolle PA; Lehr CM
Eur J Pharm Biopharm; 2016 May; 102():20-31. PubMed ID: 26940132
[TBL] [Abstract][Full Text] [Related]
30. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells.
Heit A; Maurer T; Hochrein H; Bauer S; Huster KM; Busch DH; Wagner H
J Immunol; 2003 Mar; 170(6):2802-5. PubMed ID: 12626528
[TBL] [Abstract][Full Text] [Related]
31. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
[TBL] [Abstract][Full Text] [Related]
32. Encapsulation of antigen in poly(D,L-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice.
Mohanan D; Gander B; Kündig TM; Johansen P
Eur J Pharm Biopharm; 2012 Feb; 80(2):274-81. PubMed ID: 22024408
[TBL] [Abstract][Full Text] [Related]
33. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.
Vasilakos JP; Smith RM; Gibson SJ; Lindh JM; Pederson LK; Reiter MJ; Smith MH; Tomai MA
Cell Immunol; 2000 Aug; 204(1):64-74. PubMed ID: 11006019
[TBL] [Abstract][Full Text] [Related]
35. Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo.
Rozenfeld JH; Silva SR; Ranéia PA; Faquim-Mauro E; Carmona-Ribeiro AM
J Control Release; 2012 Jun; 160(2):367-73. PubMed ID: 22036878
[TBL] [Abstract][Full Text] [Related]
36. Characterization of protein-adjuvant coencapsulation in microparticles for vaccine delivery.
Mathew S; Lendlein A; Wischke C
Eur J Pharm Biopharm; 2014 Jul; 87(2):403-7. PubMed ID: 24747810
[TBL] [Abstract][Full Text] [Related]
37. Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4
Chiodetti AL; Sánchez Vallecillo MF; Dolina JS; Crespo MI; Marin C; Schoenberger SP; Allemandi DA; Palma SD; Pistoresi-Palencia MC; Morón G; Maletto BA
Front Immunol; 2018; 9():2319. PubMed ID: 30364187
[TBL] [Abstract][Full Text] [Related]
38. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.
Tafaghodi M; Khamesipour A; Jaafari MR
Parasitol Res; 2011 May; 108(5):1265-73. PubMed ID: 21125294
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.
Diwan M; Tafaghodi M; Samuel J
J Control Release; 2002 Dec; 85(1-3):247-62. PubMed ID: 12480329
[TBL] [Abstract][Full Text] [Related]
40. Biodegradable particles as vaccine delivery systems: size matters.
Joshi VB; Geary SM; Salem AK
AAPS J; 2013 Jan; 15(1):85-94. PubMed ID: 23054976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
